This study will determine the efficacy of diuretics in patients with chronic kidney disease.
Participants with chronic kidney disease will undergo two 1-week study periods (single-dose diuretic versus single-dose placebo) separated by 1-2 weeks of washout in a cross-over design. Blood and urine samples will be collected at the end of each study period to determine the effect on urine output and to assess the kidney clearance and levels of uremic solute. Participants will weigh themselves daily.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Enrollment
17
Participants receive a single dose of metolazone.
Participants receive a single dose of placebo to match metolazone.
Stanford University
Palo Alto, California, United States
VA Palo Alto Health Care System
Palo Alto, California, United States
Change in Urine Output
Average volume of urine produced in 24 hours.
Time frame: Change from baseline urine output at 1 week for each study arm
Kidney Clearance of Uremic Solutes
Kidney clearance of uremic solutes in ml/min.
Time frame: Kidney clearance of uremic solutes at 1 week for each study arm
Change in Quality of Life Questionnaire Score
Kidney Disease Quality of Life 36 Questionnaire (KDQOL36)
Time frame: Change from baseline quality of life score at 1 week for each study arm
Plasma Urea
Time frame: Week 1
Blood Pressure
Time frame: Week 1
Weight Change
Time frame: Baseline, Week 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.